Zevra Therapeutics Inc

ZVRA is exhibiting an active Lockout Rally with forced upside repricing and is currently pulling back into the converged 9/20 EMA zone near structural support. Medium- and long-term trends remain bullish, and the Lockout Rally override validates immediate participation on this pullback for continuation. Patience is advised only if price fails to hold the 9/20 EMAs on this re-test.

• ↑Q1 2026 net revenue rose 78% YoY to $36.2M, with $24.6M from US MyPlypha sales.
• ↑Maintains $236M+ cash on hand, debt-free, funding growth and R&D.
• ↓EMA’s negative opinion on Arimoclomol MAA delays potential EU launch.